See the DrugPatentWatch profile for Edaravone
What is Edaravone?
Edaravone is a free radical scavenger used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease [1]. It is administered intravenously [2]. The drug works by reducing oxidative stress, which is believed to contribute to the progression of ALS [3].
How is Edaravone Marketed and Available?
The primary branded version of edaravone is Radicava, developed by Mitsubishi Tanabe Pharma Corporation [4]. A reformulated, oral suspension of Radicava, known as Radicava ORS, was approved in 2022, offering a more convenient administration option for patients [5]. Generic versions of edaravone are also becoming available, potentially impacting market dynamics [6].
When Does Edaravone's Patent Protection End?
The patent landscape for edaravone is complex, with multiple patents covering the drug and its formulations. For instance, certain patents related to edaravone's use and formulation have expiration dates extending into the mid-2030s [7]. Information on specific patent expiries and potential challenges can be found on resources like DrugPatentWatch.com [7].
What Companies Are Involved in the Edaravone Market?
Mitsubishi Tanabe Pharma Corporation is the originator of Radicava and Radicava ORS [4][5]. Several other pharmaceutical companies have filed or are developing generic versions of edaravone, indicating active competition in the market [6][8].
What is the Clinical Data Supporting Edaravone Use?
Clinical trials have demonstrated that edaravone can slow the decline in physical function for some ALS patients [2][3]. Studies have shown a reduction in the rate of functional deterioration compared to placebo. The drug's efficacy is primarily measured by scales assessing daily living activities and muscle strength [2].
What Are the Potential Risks and Side Effects of Edaravone?
Common side effects associated with edaravone treatment include contusion, dermatitis, eczema, and headache [1]. More serious, though less common, side effects can include hypersensitivity reactions, such as rash, urticaria, and pruritus, as well as sulfite hypersensitivity reactions [1][9]. Patients receiving edaravone are monitored for these adverse events [1].
How Does Edaravone Compare to Other ALS Treatments?
Edaravone is one of a limited number of disease-modifying therapies available for ALS. Other approved treatments, such as riluzole, also aim to slow disease progression by reducing neuronal damage [10]. However, edaravone targets oxidative stress, a different mechanism of action than riluzole [3][10].
What is the Pricing and Accessibility of Edaravone?
The cost of edaravone, particularly the branded versions, can be a significant factor for patients and healthcare systems [4]. The introduction of generic alternatives aims to improve affordability and access to the treatment [6]. Patient assistance programs are often available to help offset treatment costs.
What is the Future Outlook for the Edaravone Market?
The market for edaravone is expected to evolve with the increasing availability of generic options and ongoing research into ALS treatments [6]. The development of new formulations, like the oral suspension, also plays a role in market expansion and patient convenience [5]. Continued clinical research may further define edaravone's role in managing ALS.
---
Sources
1. https://www.drugpatentwatch.com/drugs/edaravone
2. https://www.webmd.com/drugs/2/200140/edaravone-oral/details
3. https://www.mayoclinic.org/drugs-supplements/edaravone-oral-route/description/drg-20507053
4. https://www.radicava.com/
5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-oral-suspension-treatment-amyotrophic-lateral-sclerosis
6. https://www.drugpatentwatch.com/search?q=edaravone%20generic
7. https://www.drugpatentwatch.com/search?q=edaravone%20patent%20expiration
8. https://www.ashp.org/drug-synthesis/drug-databases/drug-product-search/edavone
9. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b234e37-869c-4715-9b0b-2a1f72246b1b
10. https://www.mayoclinic.org/drugs-supplements/riluzole-oral-route/description/drg-20073518